Klemens A.
- Country
- Austria
- Department
- Department of Internal Medicine, Division of Cardiology
Research Overview
- Efficacy and Safety Evaluation of Eplontersen in Transthyretin-Mediated Amyloid Cardiomyopathy: A Phase 3 Double-Blind, Randomized, Placebo-Controlled Study
- TRITON-CM: A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Nucresiran in Patients with Transthyretin-Mediated Amyloidosis with Cardiomyopathy (ATTR amyloidosis with cardiomyopathy)
- An Open-Label Extension Study to Assess the Long-Term Safety of Eplontersen (ION-682884) in Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Data & Insights
Has run more than one trial at 36 of 131 partner sites.
Specializations
Cardiovascular Research
This investigator specializes in studying Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM), a progressive cardiac condition affecting heart function and structure.
- Cardiomyopathy Management
- Novel Therapeutic Approaches
- Long-term Treatment Assessment
The research focus encompasses cardiovascular outcomes and therapeutic interventions for cardiac amyloidosis.
Rare Disease Research
The investigator conducts studies in rare cardiac disorders, with particular emphasis on protein misfolding conditions affecting the heart.
- Amyloidosis Therapeutics
- Disease Progression Monitoring
- Standard of Care Enhancement
Their work aims to advance understanding and treatment of rare cardiac conditions through clinical investigation.
Clinical Safety Studies
The investigator evaluates long-term safety profiles and therapeutic effectiveness of novel treatments for cardiac conditions.
- Safety Assessment
- Extended Treatment Evaluation
- Cardiovascular Event Prevention
Their research includes comprehensive monitoring of cardiovascular outcomes and treatment tolerability.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.